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Summary Recent years have seen the introduction of a number of whole-blood 
assays, in which unseparated heparinized blood is stimulated with antigen either 
overnight or for as long as 6 days, and cytokine production is measured in the plasma 
or supernatant. These assays have potential for use in the field as immunodiagnostic 
assays, as they require only a small blood sample and basic laboratory facilities. Use 
of these assays in a large study of the immunological effects of BeG vaccination in 
Malawi has shown that the diluted blood, 6-day whole-blood assay is robust, and can 
be used to assess T-cell responses to both crude and recombinant antigens. If used 
with antigens specific to Mycobacterium leprae, these assays could be used to 
measure exposure to M. leprae within communities or populations, or to aid the 
early diagnosis of leprosy. 
Whole blood assays, in which heparinized whole blood, rather than gradient-separated, 
peripheral blood mononuclear cells (PBMC), is used to study cell function, can be employed 
to measure both lymphocyte proliferation and cytokine production. As the blood is simply 
diluted and placed in culture with the appropriate stimulus, the assays are far simpler and 
quicker to set up than conventional assays using PBMC, and can be performed in laboratories 
with only basic facilities. This means that they can be used in a community, to study the 
immune response to exposure to Mycobacterium leprae. 
Whole-blood assays are being used increasingly for research or diagnosis. l In these 
assays, undiluted blood can be incubated with antigen overnight,2,3 or blood, diluted 1 :  10 or 
1 :5 ,  can be incubated for 5-6 days.4-6 We have been using heparinized blood diluted 1 :  10, 
which is incubated with antigens or rnitogens at 37°C in an atmosphere of 5% CO2 ; 
supernatants are collected after 5-6 days to measure T-cell-derived cytokines. Our initial 
studies in Nepal showed that the IFN--y response to fractionated leprosy antigens correlated 
with position in the leprosy spectrum.? 
We are now employing this method in a large, field-based study of the immune response 
to BCG vaccination in Malawi, where BCG has previously been shown to provide some 
protection against leprosy, but not against pulmonary tuberculosis; 8 a parallel study is being 
performed in the United Kingdom. In Malawi, testing of skin-test sensitivity and cytokine 
production to mycobacterial antigens was performed in 635 individuals, who were then 
randomly allocated, so that two-thirds received BCG vaccination and one-third placebo. The 
results of pre-vaccination testing of the IFN--y responses are now available, permitting us to 
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evaluate the practicalities of using such whole-blood assays on a broad scale, and to 
determine whether they are sufficiently robust for field use. 
One problem with performing such assays over time, and under field conditions, in which 
the ambient temperature in the laboratory may vary considerably during the year, is to control 
for the performance and reproducibility of the cytokine ELISAs. We have used aliquots of a 
positive control supernatant, obtained by incubating bulk cultures of heparinized whole blood 
diluted 1 :  10 with phytohaemagglutinin, a mitogen, for 3 days, as a biological control that is 
included on each plate ; this has produced a coefficient of variation of 1 8% .  Such supernatants 
can also be exchanged between laboratories, to ensure comparability of the quantities of 
cytokine measured. Comparison of the standard curves run on each ELISA plate also reveals 
changes in sensitivity of the assay. The reproducibility of whole-blood cytokine responses 
over time within the same individual is also an issue. In a study in the UK and Nepal, the 
responses of individual controls and patients tested monthly over 6 months proved 
consistent.9 
Responses to a panel of purified protein derivatives (PPDs) from a range of mycobacterial 
species have been used in the Malawi study to assess exposure to pathogenic and environ­
mental mycobacteria. Using the antigens at a concentration of 5 p,g per mI, and a cut-off of 
62 pg per mI of IFN-'Y to define a responder, responders and non-responders were detected to 
all of the antigens used. Overall, frequency distributions indicated that, in Malawi, exposure 
to some of the environmental mycobacteria such as M. avium may be greater than that to 
M. tuberculosis (Black, Fine and Dockrell, unpublished results) .  
I t  was also important to assess whether assays performed on diluted whole blood are 
sufficiently sensitive to allow detection of the responses to individual recombinant antigens, 
particularly as cultures of blood diluted 1 :  10 contain only approximately one-quarter of the 
mononuclear cells used in standard PBMC assays. A panel of recombinant antigens from M. 
tuberculosis, M. leprae, and M. bovis has been used. Results indicate that, although the 
proportion of responders to individual antigens, and the median IFN-'Y produced are lower 
than those obtained with crude PPD preparations, the assays are sufficiently sensitive to 
detect responses to the recombinant antigens, and to reveal varying responses to those derived 
from the different mycobacteria (Black, Fine and Dockrell, unpublished results). 
Another question of interest is whether the results of such IFN-'Y assays parallel the results 
obtained by skin testing; if so, these assays could be used to screen leprosy antigens or 
fractions for those of diagnostic potential, prior to their formulation as skin-test reagents.  
Alternatively, whole-blood assays could be used instead of a skin test; although a small blood 
sample is required, a repeat visit to read the skin test is not required. Whole blood tests have 
been proposed as an alternative to skin testing for the diagnosis of tuberculosis .2,3 When the 
IFN-'Y response induced in vitro by PPD (RT48, Statens Serum Institut, Copenhagen) was 
compared to the induration measured 48-72 h after skin testing with 2 TU of PPD RT23,  a 
very high correlation was obtained between the median IFN-'Y-response and induration, J O  
suggesting that these responses are correlated in the majority of individuals ,  although there 
are exceptions-individuals who respond in one test or the other, but not in both. 
In conclusion, whole blood assays, using heparinized blood diluted 1 :  1 0, and stimulated 
with antigen for 6 days, allow measurement of cytokines such as IFN-'Y in large-scale field 
studies. The ELISA method for detection of cytokine is robust, and the inclusion of control 
supernatants allows assay variability to be monitored. The responses in healthy individuals 
appear stable over time. These assays allow responses to both crude antigens such as 
PPDs and individual recombinant antigens to be evaluated. The 6-day IFN-'Y response to 
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M. tuberculosis PPD shows a strong association with induration measured by skin testing to 
the same antigen. If used with M. leprae-specific antigens, such whole blood tests have 
potential as field tools with which to monitor exposure to M. leprae within communities, or as 
a diagnostic test to aid the early diagnosis of leprosy. 
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